Andrew Combs, Chief Chemistry Officer at Prelude Therapeutics Inc (PRLD), bought 63,075 shares at $1.37 ($86K) on 2024-12-23, disclosed to the SEC on 2024-12-26.
Open-market purchase of $86k PRLD by Chief Chemistry Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.15 | 3,075 | $4K | 4.1% |
| 2 | $1.37 | 60,000 | $82K | 95.9% |
| Total | $1.36 avg | 63,075 | $86K | 100% |
| Filing → |
| PRLD | BUY | 2020-09-29 | $19K | — | Filing → |